Deubiquitinase MYSM1 Drives Myocardial Ischemia/reperfusion Injury by Stabilizing STAT1 in Cardiomyocytes

Overview

Journal Theranostics

Date 2025 Feb 3

PMID 39897566

Authors

Xiaowen Shi

Jianjiang Xu

Lei Liu

Shenggang Zhao

Yuanyuan Qian

Zimin Fang

Liming Lin

Xia Zhao

Shangcai Xie

Fengjie Shi

Jibo Han

Affiliations

Soon will be listed here.

Abstract

Myocardial ischemia/reperfusion (I/R) injury leads to irreversible cardiomyocyte death and aggravates myocardial infarction. Deubiquitinating enzymes (DUBs) are essential for maintaining substrate protein stability and functionality, playing significant roles in cardiac pathophysiology. In this study, we aimed to clarify the regulatory role of a DUB, Myb-like, SWIRM, and MPN domains 1 protein (MYSM1), in myocardial I/R injury and explore the molecular mechanism behind. Firstly, it was found that the expression of MYSM1 positively correlates with myocardial I/R injury. Genetic knockdown of MYSM1 significantly conferred protection against I/R injury in hearts. Correspondingly, AAV9-mediated cardiomyocyte-specific knockdown of MYSM1 had a therapeutic effect on myocardial I/R injury. Through a comprehensive proteome-wide quantitative analysis, we identified signal transducer and activator of transcription 1 (STAT1) as the direct substrate of MYSM1. Mechanistically, MYSM1 mediated the K63-linked deubiquitination and stabilization of STAT1 at position K379 via its MPN metalloprotease domain. Additionally, MYSM1 initiates the expression of necroptosis-related genes by promoting the transcription factor function of STAT1. This study illustrated a MYSM1-STAT1 axis in regulating myocardial I/R injury and identified MYSM1 as a pharmacological target for myocardial I/R injury.

References

Jiang X, Nguyen Q, Chou Y, Wang T, Nandakumar V, Yates P . Control of B cell development by the histone H2A deubiquitinase MYSM1. Immunity. 2011; 35(6):883-96. PMC: 4098839. DOI: 10.1016/j.immuni.2011.11.010. View

Bolli R, Dawn B, Xuan Y . Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med. 2003; 13(2):72-9. DOI: 10.1016/s1050-1738(02)00230-x. View

Hu X, Li J, Fu M, Zhao X, Wang W . The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021; 6(1):402. PMC: 8617206. DOI: 10.1038/s41392-021-00791-1. View

Zhen C, Liu H, Gao L, Tong Y, He C . Signal transducer and transcriptional activation 1 protects against pressure overload-induced cardiac hypertrophy. FASEB J. 2020; 35(1):e21240. DOI: 10.1096/fj.202000325RRR. View

Schindler C, Darnell Jr J . Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 1995; 64:621-51. DOI: 10.1146/annurev.bi.64.070195.003201. View

Kim H, Lee M . STAT1 as a key modulator of cell death. Cell Signal. 2006; 19(3):454-65. DOI: 10.1016/j.cellsig.2006.09.003. View

Ye B, Shi X, Xu J, Dai S, Xu J, Fan X . Gasdermin D mediates doxorubicin-induced cardiomyocyte pyroptosis and cardiotoxicity via directly binding to doxorubicin and changes in mitochondrial damage. Transl Res. 2022; 248:36-50. DOI: 10.1016/j.trsl.2022.05.001. View

Popovic D, Vucic D, Dikic I . Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014; 20(11):1242-53. DOI: 10.1038/nm.3739. View

Bostrom P, Mann N, Wu J, Quintero P, Plovie E, Panakova D . C/EBPβ controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell. 2010; 143(7):1072-83. PMC: 3035164. DOI: 10.1016/j.cell.2010.11.036. View

10.

Tang L, Zhou Y, Xiong X, Li N, Zhang J, Luo X . Ubiquitin-specific protease 7 promotes ferroptosis via activation of the p53/TfR1 pathway in the rat hearts after ischemia/reperfusion. Free Radic Biol Med. 2020; 162:339-352. DOI: 10.1016/j.freeradbiomed.2020.10.307. View

11.

Wang T, Nandakumar V, Jiang X, Jones L, Yang A, Huang X . The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation. Blood. 2013; 122(16):2812-22. PMC: 3798996. DOI: 10.1182/blood-2013-03-489641. View

12.

Qian C, Zhang Q, Li S, Zeng L, Walsh M, Zhou M . Structure and chromosomal DNA binding of the SWIRM domain. Nat Struct Mol Biol. 2005; 12(12):1078-85. DOI: 10.1038/nsmb1022. View

13.

Karbassi E, Fenix A, Marchiano S, Muraoka N, Nakamura K, Yang X . Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine. Nat Rev Cardiol. 2020; 17(6):341-359. PMC: 7239749. DOI: 10.1038/s41569-019-0331-x. View

14.

Xiang Q, Yi X, Zhu X, Wei X, Jiang D . Regulated cell death in myocardial ischemia-reperfusion injury. Trends Endocrinol Metab. 2023; 35(3):219-234. DOI: 10.1016/j.tem.2023.10.010. View

15.

Stephanou A, Brar B, Scarabelli T, Jonassen A, Yellon D, Marber M . Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J Biol Chem. 2000; 275(14):10002-8. DOI: 10.1074/jbc.275.14.10002. View

16.

Liang Y, Bhatt G, Tung L, Wang H, Kim J, Mousa M . Deubiquitinase catalytic activity of MYSM1 is essential in vivo for hematopoiesis and immune cell development. Sci Rep. 2023; 13(1):338. PMC: 9825392. DOI: 10.1038/s41598-023-27486-7. View

17.

Liu L, Pang J, Qin D, Li R, Zou D, Chi K . Deubiquitinase OTUD5 as a Novel Protector against 4-HNE-Triggered Ferroptosis in Myocardial Ischemia/Reperfusion Injury. Adv Sci (Weinh). 2023; 10(28):e2301852. PMC: 10558642. DOI: 10.1002/advs.202301852. View

18.

Pan X, Wu S, Wei W, Chen Z, Wu Y, Gong K . Structural and Functional Basis of JAMM Deubiquitinating Enzymes in Disease. Biomolecules. 2022; 12(7). PMC: 9313428. DOI: 10.3390/biom12070910. View

19.

Panda S, Nilsson J, Gekara N . Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes. Immunity. 2015; 43(4):647-59. DOI: 10.1016/j.immuni.2015.09.010. View

20.

Reyes-Turcu F, Ventii K, Wilkinson K . Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem. 2009; 78:363-97. PMC: 2734102. DOI: 10.1146/annurev.biochem.78.082307.091526. View